Understanding the causes and prevention of neural tube defects: Insights from the splotch mouse model

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 85, Issue 4, 2009, Pages 322-330

  Greene, Nicholas D E ^a   Massa, Valentina ^a   Copp, Andrew J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Diet; Exencephaly; Folate; Folic acid; Neural tube defects; Pax3; Spina bifida; Splotch

Indexed keywords

FOLIC ACID; TERATOGENIC AGENT; TRANSCRIPTION FACTOR PAX3;

APOPTOSIS; CELL ADHESION; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; FOLIC ACID DEFICIENCY; GENE EXPRESSION; GENE FUNCTION; GENE INTERACTION; GENE MUTATION; GENETIC PREDISPOSITION; GENETICS; HOMOZYGOSITY; HUMAN; NEURAL TUBE; NEURAL TUBE DEFECT; NONHUMAN; PRIORITY JOURNAL; REVIEW; VITAMIN SUPPLEMENTATION;

ANIMALS; DISEASE MODELS, ANIMAL; EMBRYO, MAMMALIAN; ENVIRONMENT; EPISTASIS, GENETIC; FOLIC ACID; FOLIC ACID DEFICIENCY; HUMANS; MICE; MICE, TRANSGENIC; NEURAL TUBE DEFECTS; PAIRED BOX TRANSCRIPTION FACTORS;

MUS;

EID: 65349125846     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.20539     Document Type: Review

References (104)

1. Auerbach R. 1954. Analysis of the developmental effects of a lethal mutation in the house mouse. J Exp Zool 127:305-329.
2. Ayme S, Philip N. 1995. Possible homozygous Waardenburg syndrome in a fetus with exencephaly. Am J Med Genet 59:263-265.
3. Baldwin CT, Hoth CF, Macina RA et al. 1995. Mutations in PAX3 that cause Waardenburg syndrome type I: ten new mutations and review of the literature. Am J Med Genet 58:115-122.
4. Beechey CV, Searle AG. 1986. Mutations at the Sp locus. Mouse News Letter 75:28.
5. Begum S, Emani N, Cheung A, et al. 2005. Cell-type-specific regulation of distinct sets of gene targets by Pax3 and Pax3/FKHR. Oncogene 24:1860-1872.
6. Bennett GD, An J, Craig JC, et al. 1998. Neurulation abnormalities secondary to altered gene expression in neural tube defect susceptible splotch embryos. Teratology 57:17-29.
7. Bennett GD, Vanwaes J, Moser K, et al. 2006. Failure of homocysteine to induce neural tube defects in a mouse model. Birth Defects Res B Dev Reprod Toxicol 77:89-94.
8. Blom HJ, Shaw GM, den HM, et al. 2006. Neural tube defects and folate: case far from closed. Nat Rev Neurosci 7:724-731.
9. Bober E, Franz T, Arnold H-H, et al. 1994. Pax-3 is required for the development of limb muscles: a possible role for the migration of dermomyotomal muscle progenitor cells. Development 120:603-612.
10. Borycki AG, Li J, Jin FZ, et al. 1999. Pax3 functions in cell survival and in Pax7 regulation. Development 126:1665-1674.
11. Buckingham M, Relaix F. 2007. The role of Pax genes in the development of tissues and organs: Pax3 and Pax7 regulate muscle progenitor cell functions. Annu Rev Cell Dev Biol 23:645-673.
12. Burgoon JM, Selhub J, Nadeau M, et al. 2002. Investigation of the effects of folate deficiency on embryonic development through the establishment of a folate deficient mouse model. Teratology 65:219-227.
13. Burren KA, Savery D, Massa V, et al. 2008. Gene environment interactions in the causation of neural tube defects: folate deficiency increases susceptibility conferred by loss of Pax3 function. Hum Mol Genet 17:3675-3685.
14. Carezani-Gavin M, Clarren SK, Steege T. 1992. Waardenburg syndrome associated with meningomyelocele. Am J Med Genet 42:135-136.
15. Chalepakis G, Goulding M, Read A, et al. 1994. Molecular basis of splotch and Waardenburg Pax-3 mutations. Proc Natl Acad Sci U S A 91:3685-3689.
16. Chatkupt S, Johnson WG. 1993. Waardenburg syndrome and myelomeningocele in a family. J Med Genet 30:83-84.
17. 2H Pax3 mouse mutant. Cardiovasc Res 47:314-328.
18. Conway SJ, Henderson DJ, Anderson RH, et al. 1997. Development of a lethal congenital heart defect in the splotch (Pax3) mutant mouse. Cardiovasc Res 36:163-173.
19. Copp AJ. 2005. Neurulation in the cranial region: normal and abnormal. J Anat 207:623-635.
20. Copp AJ, Greene NDE, Murdoch JN. 2003. The genetic basis of mammalian neurulation. Nat Rev Genet 4:784-793.
21. Dickie MM. 1964. New splotch alleles in the mouse. J Hered 55:97-101.
22. 2H) mutant: putative roles for Pax3 and PDGFRa in rib patterning. Anat Rec 255:353-361.
23. Dunlevy LP, Burren KA, Chitty LS, et al. 2006a. Excess methionine suppresses the methylation cycle and inhibits neural tube closure in mouse embryos. FEBS Lett 580:2803-2807.
24. Dunlevy LP, Burren KA, Mills K, et al. 2006b. Integrity of the methylation cycle is essential for mammalian neural tube closure. Birth Defects Res A Clin Mol Teratol 76:544-552.
25. Dunlevy LP, Chitty LS, Burren KA, et al. 2007. Abnormal folate metabolism in foetuses affected by neural tube defects. Brain 130:1043-1049.
26. Eichholzer M, Tonz O, Zimmermann R. 2006. Folic acid: a public-health challenge. Lancet 367:1352-1361.
27. Engleka KA, Gitler AD, Zhang MZ, et al. 2005. Insertion of Cre into the Pax3 locus creates a new allele of Splotch and identifies unexpected Pax3 derivatives. Dev Biol 280:396-406.
28. Epstein DJ, Vekemans M, Gros P. 1991. Splotch (Sp2H), a mutation affecting development of the mouse neural tube, shows a deletion within the paired homeodomain of Pax-3. Cell 67:767-774.
29. Epstein DJ, Vogan KJ, Trasler DG et al. 1993. A mutation within intron 3 of the Pax-3 gene produces aberrantly spliced mRNA transcripts in the splotch (Sp) mouse mutant. Proc Natl Acad Sci U S A 90:532-536.
30. Epstein JA, Lam P, Jepeal L, et al. 1995. Pax3 inhibits myogenic differentiation of cultured myoblast cells. J Biol Chem 270:11719-11722.
31. Fine EL, Horal M, Chang TI, et al. 1999. Evidence that elevated glucose causes altered gene expression, apoptosis, and neural tube defects in a mouse model of diabetic pregnancy. Diabetes 48:2454-2462.
32. Fleming A, Copp AJ. 1998. Embryonic folate metabolism and mouse neural tube defects. Science 280:2107-2109.
33. Fleming A, Copp AJ. 2000. A genetic risk factor for mouse neural tube defects: defining the embryonic basis. Hum Mol Genet 9:575-581.
34. 4H deletion may contain a new locus essential for postimplantation development. Genomics 34:205-212.
35. d alleles: differential phenotypic effects on neural crest and limb musculature. Anat Embryol 187:371-377.
36. Franz T, KotharyR, Surani MAH, et al. 1993. The Splotchmutationinterferes with muscle development in the limbs. Anat Embryol 187:153-160.
37. Gamble MV, Liu X, Slavkovich V, et al. 2007. Folic acid supplementation lowers blood arsenic. Am J Clin Nutr 86:1202-1209.
38. Gefrides LA, Bennett GD, Finnell RH. 2002. Effects of folate supplementation on the risk of spontaneous and induced neural tube defects in splotch mice. Teratology 65:63-69.
39. Gelineau-van Waes WJ, Heller S, Bauer LK, et al. 2008. Embryonic development in the reduced folate carrier knockout mouse is modulated by maternal folate supplementation. Birth Defects Res A Clin Mol Teratol 82:494-507.
40. Goulding M, Lumsden A, Paquette AJ. 1994. Regulation of Pax-3 expression in the dermomyotome and its role in muscle development. Development 120:957-971.
41. Goulding M, Sterrer S, Fleming J, et al. 1993. Analysis of the Pax-3 gene in the mouse mutant splotch. Genomics 17:355-363.
42. Goulding MD, Chalepakis G, Deutsch U, et al. 1991. Pax-3, a novel murine DNA binding protein expressed during early neurogenesis. EMBO J 10:1135-1147.
43. Greene ND, Copp AJ. 2005. Mouse models of neural tube defects: investigating preventive mechanisms. Am J Med Genet C Semin Med Genet 135:31-41.
44. Greene NDE, Dunlevy LE, Copp AJ. 2003. Homocysteine is embryotoxic but does not cause neural tube defects in mouse embryos. Anat Embryol 206:185-191.
45. Harris MJ, Juriloff DM. 2007. Mouse mutants with neural tube closure defects and their role in understanding human neural tube defects. Birth Defects Res A Clin Mol Teratol 79:187-210.
46. Harris SL, Levine AJ. 2005. The p53 pathway: positive and negative feedback loops. Oncogene 24:2899-2908.
47. Heid MK, Bills ND, Hinrichs SH, et al. 1992. Folate deficiency alone does not produce neural tube defects in mice. J Nutr 122:888-894.
48. 2H mouse reveal a role for Pax3 in specification of the ventrolateral and posterior parts of the somite. Dev Biol 209:143-158.
49. Hol FA, Hamel BCJ, Geurds MPA, et al. 1995. A frameshift mutation in the gene for PAX3 in a girl with spina bifida and mild signs of Waardenburg syndrome. J Med Genet 32:52-56. Honein MA, Paulozzi LJ, Mathews TJ, et al. 2001. Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. JAMA 285:2981-2986.
50. Juriloff DM, Harris MJ, Tom C, et al. 1991. Normal mouse strains differ in the site of initiation of closure of the cranial neural tube. Teratology 44:225-233.
51. Kalter H. 2000. Folic acid and human malformations: a summary and evaluation. Reprod Toxicol 14:463-476.
52. Kapron-Bras CM, Trasler DG. 1988a. Histological comparison of the effects of the splotch gene and retinoic acid on the closure of the mouse neural tube. Teratology 37:389-399.
53. Kapron-Bras CM, Trasler DG. 1988b. Interaction between the splotch mutation and retinoic acid in mouse neural tube defects in vitro. Teratology 38:165-173.
54. Killman S-A. 1964. Effect of deoxyuridine on incorporation of tritiated thymidine: difference between normoblasts and megaloblasts. Acta Med Scand 175:483-488.
55. Kirke PN, Molloy AM, Daly LE, et al. 1993. Maternal plasma folate and
56. 12 are independent risk factors for neural tube defects. Q J Med 86:703-708.
57. Koblar SA, Murphy M, Barrett GL, et al. 1999. Pax-3 regulates neurogenesis in neural crest-derived precursor cells. J Neurosci Res 56:518-530.
58. Kwang SJ, Brugger SM, Lazik A, et al. 2002. Msx2 is an immediate downstream effector of Pax3 in the development of the murine cardiac neural crest. Development 129:527-538.
59. Lang D, Chen F, Milewski R, et al. 2000. Pax3 is required for enteric ganglia formation and functions with Sox10 to modulate expression of cret. J Clin Invest 106:963-971.
60. Lang D, Lu MM, Huang L, et al. 2005. Pax3 functions at a nodal point in melanocyte stem cell differentiation. Nature 433:884-887.
61. Li D, Pickell L, Liu Y, et al. 2006. Impact of methylenetetrahydrofolate reductase deficiency and low dietary folate on the development of neural tube defects in splotch mice. Birth Defects Res A Clin Mol Teratol 76:55-59.
62. Li J, Liu KC, Jin F, et al. 1999. Transgenic rescue of congenital heart disease and spina bifida in Splotch mice. Development 126:2495-2503.
63. Lindgren A, Danielsson BR, Dencker L, et al. 1984. Embryotoxicity of arsenite and arsenate: distribution in pregnant mice and monkeys and effects on embryonic cells in vitro. Acta Pharmacol Toxicol (Copenh) 54:311-320.
64. Lu W, Zhu H, Wen S, et al. 2007. Screening for novel PAX3 polymorphisms and risks of spina bifida. Birth Defects Res A Clin Mol Teratol 79:45-49.
65. Machado AF, Hovland DN, Jr, Pilafas S, et al. 1999. Teratogenic response to arsenite during neurulation: relative sensitivities of C57BL/6J and SWV/Fnn mice and impact of the splotch allele. Toxicol Sci 51:98-107.
66. Machado AF, Martin LJ, Collins MD. 2001a. Pax3 and the splotch mutations: structure, function, and relationship to teratogenesis, including gene-chemical interactions. Curr Pharm Des 7:751-785.
67. Machado AF, Zimmerman EF, Hovland DN Jr, et al. 2001b. Diabetic embryopathy in C57BL/6J mice - altered fetal sex ratio and impact of the splotch allele. Diabetes 50:1193-1199.
68. Mansouri A, Pla P, Larue L, et al. 2001. Pax3 acts cell autonomously in the neural tube and somites by controlling cell surface properties. Development 128:1995-2005.
69. Martin LJ, Machado AF, Loza MA, et al. 2003. Effect of arsenite, maternal age, and embryonic sex on spina bifida, exencephaly, and resorption rates in the splotch mouse. Birth Defects Res A Clin Mol Teratol 67:231-239.
70. Mayanil CS, George D, Freilich L, et al. 2001. Microarray analysis detects novel Pax3 downstream target genes. J Biol Chem 276:49299-49309.
71. Mayanil CS, Pool A, Nakazaki H, et al. 2006. Regulation of murine TGFbeta2 by Pax3 during early embryonic development. J Biol Chem 281:24544-24552.
72. Mersereau P, Kilker K, Carter H, et al. 2004. Spina bifida and anencephaly before and after folic acid mandate--United States, 1995-1996 and 1999-2000. MMWR Morb Motal Wkly Rep 53:362-365.
73. Moase CE, Trasler DG. 1987. Retinoic acid-induced selective mortality of splotch-delayed mouse neural tube defect mutants. Teratology 36:335-343.
74. Moase CE, Trasler DG. 1989. Spinal ganglia reduction in the splotch-delayed mouse neural tube defect mutant. Teratology 40:67-75.
75. Morrissey RE, Mottet NK. 1983. Arsenic-induced exencephaly in the mouse and associated lesions occurring during neurulation. Teratology 28:399-411.
76. Nakazaki H, Reddy AC, Mania-Farnell BL, et al. 2008. Key basic helix-loop-helix transcription factor genes Hes1 and Ngn2 are regulated by Pax3 during mouse embryonic development. Dev Biol 316:510-523.
77. Nye JS, Balkin N, Lucas H et al. 1998. Myelomeningocele and Waardenburg syndrome (Type 3) in patients with interstitial deletions of 2q35 and the PAX3 gene: possible digenic inheritance of a neural tube defect. Am J Med Genet 75:401-408.
78. Pani L, Horal M, Loeken MR. 2002. Rescue of neural tube defects in Pax-3-deficient embryos by p53 loss of function: implications for Pax-3-dependent development and tumorigenesis. Genes Dev 16:676-680.
79. Phelan SA, Ito M, Loeken MR. 1997. Neural tube defects in embryos of diabetic mice: role of the Pax-3 gene and apoptosis. Diabetes 46:1189-1197.
80. Piedrahita JA, Oetama B, Bennett GD et al. 1999. Mice lacking the folic acid-binding protein Folbp1 are defective in early embryonic development. Nature Genet 23:228-232.
81. Russell WL. 1947. Splotch: a new mutation in the house mouse. Genetics 32:350-358.
82. Said HM. 2004. Recent advances in carrier-mediated intestinal absorption of water-soluble vitamins. Annu Rev Physiol 66:419-446.
83. Scott JM. 1999. Folate and vitamin B12. Proc Nutr Soc 58:441-448.
84. Shalat SL, Walker DB, Finnell RH. 1996. Role of arsenic as a reproductive toxin with particular attention to neural tube defects. J Toxicol Environ Health 48:253-272.
85. Smithells RW, Sheppard S, Schorah CJ, et al. 1980. Possible prevention of neural-tube defects by periconceptional vitamin supplementation. Lancet 1:339-340.
86. Spiegelstein O, Mitchell LE, Merriweather MY, et al. 2004. Embryonic development of folate binding protein-1 (Folbp1) knockout mice: effects of the chemical form, dose, and timing of maternal folate supplementation. Dev Dyn 231:221-231.
87. Tajbakhsh S, Rocancourt D, Cossu G et al. 1997. Redefining the genetic hierarchies controlling skeletal myogenesis: Pax-3 and Myf-5 act upstream of MyoD. Cell 89:127-138.
88. Tassabehji M, Read AP, Newton VE et al. 1992. Waardenburg's syndrome patients have mutations in the human homologue of the Pax-3 paired box gene. Nature 355:635-636.
89. Trembath D, Sherbondy AL, Vandyke DC et al. 1999. Analysis of select folate pathway genes, PAX3, and human T in a Midwestern neural tube defect population Teratology 59:331-341.
90. Tremblay P, Pituello F, Gruss P. 1996. Inhibition of floor plate differentiation by Pax3: evidence from ectopic expression in transgenic mice. Development 122:2555-2567.
91. Van der Put NMJ, Van Straaten HWM, Trijbels FJM, et al. 2001. Folate, homocysteine and neural tube defects: an overview. Exp Biol Med (Maywood) 226:243-270.
92. VanAerts LAGJM, Blom HJ, Deabreu RA et al. 1994. Prevention of neural tube defects by and toxicity of L-homocysteine in cultured postim-plantation rat embryos. Teratology 50:348-360.
93. d) mouse mutant carries a point mutation within the paired box of the Pax-3 gene. Genomics 17:364-369.
94. Wald N, Sneddon J, Densem J et al. 1991. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 338:131-137.
95. Wang A, Holladay SD, Wolf DC, et al. 2006. Reproductive and developmental toxicity of arsenic in rodents: a review. Int J Toxicol 25:319-331.
96. Wang Q, Kumar S, Mitsios N, et al. 2007. Investigation of downstream target genes of PAX3c, PAX3e and PAX3g isoforms in melanocytes by microarray analysis Int J Cancer 120:1223-1231.
97. Wlodarczyk B, Spiegelstein O, Gelineau-van Waes J, et al. 2001. Arsenicinduced congenital malformations in genetically susceptible folate binding protein-2 knockout mice. Toxicol Appl Pharmacol 177:238-246.
98. Wlodarczyk BJ, Bennett GD, Calvin JA, et al. 1996. Arsenic-induced neural tube defects in mice: alterations in cell cycle gene expression. Reprod Toxicol 10:447-454.
99. Wlodarczyk BJ, Tang LS, Triplett A, et al. 2006. Spontaneous neural tube defects in splotch mice supplemented with selected micronutrients. Toxicol Appl Pharmacol 213:55-63.
100. Wollnik B, Tukel T, Uyguner O, et al. 2003. Homozygous and heterozygous inheritance of PAX3 mutations causes different types of Waardenburg syndrome. Am J Med Genet 122A:42-45.
101. Wu M, Li J, Engleka KA, et al. 2008. Persistent expression of Pax3 in the neural crest causes cleft palate and defective osteogenesis in mice. J Clin Invest 118:2076-2087.
102. Zhao RB, Russell RG, Wang YH, et al. 2001. Rescue of embryonic lethality in reduced folate carrier-deficient mice by maternal folic acid supplementation reveals early neonatal failure of hematopoietic organs. J Biol Chem 276:10224-10228.
103. Zhou HM, Wang J, Rogers R, et al. 2008. Lineage-specific responses to reduced embryonic Pax3 expression levels. Dev Biol 315:369-382.
104. Zlotogora J, Lerer I, Bar-David S, et al. 1995. Homozygosity for Waardenburg syndrome. Am J Hum Genet 56:1173-1178.